Liling Wan
Impact in
- Cancer Research top 5%
- Oncology top 5%
- Peptidase Inhibition and Analysis
- Cancer Cells and Metastasis
Papers in
-
- Protein Degradation and Inhibitors 5
- Genomics and Chromatin Dynamics 4
- Histone Deacetylase Inhibitors Research 3
- RNA modifications and cancer 3
- RNA Research and Splicing 3
- Ubiquitin and proteasome pathways 2
-
- Cancer Mechanisms and Therapy 7
- Co-authors
- Yibin Kang (8 shared papers)Klaus Pantel (1 shared paper)Haitao Li (5 shared papers)C. David Allis (4 shared papers)Xiaobing Shi (3 shared papers)Hong Wen (2 shared papers)Yuanyuan Li (2 shared papers)Tatyana Panchenko (1 shared paper)
- Journals
- Nature Communications (2 papers)Cancer Research (2 papers)Molecular Cell (2 papers)Nature Chemical Biology (1 paper)Blood (1 paper)
- Partner nations
- United StatesChinaHong Kong
In The Last Decade
Liling Wan
20 papers receiving 1.6k citations
Liling Wan's Hit Papers
Peers
Comparison fields: 5 of 85
- Cancer Research 295
- Oncology 498
- Pathology and Forensic Medicine 266
- Molecular Biology 1.0k
- Geriatrics and Gerontology 32
Countries citing papers authored by Liling Wan
This map shows the geographic impact of Liling Wan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liling Wan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liling Wan more than expected).
Fields of papers citing papers by Liling Wan
This network shows the impact of papers produced by Liling Wan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liling Wan. The network helps show where Liling Wan may publish in the future.
Co-authors
The 25 scholars most cited alongside Liling Wan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Tumor metastasis: moving new biological insights into the clinic Hit paper breakdown → | 2013 | 636 |
| 2 | 2016 | 287 | |
| 3 | 2017 | 195 | |
| 4 | 2014 | 112 | |
| 5 | 2018 | 84 | |
| 6 | 2021 | 49 | |
| 7 | 2022 | 48 | |
| 8 | 2014 | 41 | |
| 9 | 2014 | 38 | |
| 10 | 2013 | 37 | |
| 11 | 2020 | 37 | |
| 12 | 2013 | 31 | |
| 13 | 2023 | 17 | |
| 14 | 2024 | 11 | |
| 15 | 2023 | 8 | |
| 16 | 2024 | 6 | |
| 17 | 2024 | 5 | |
| 18 | 2024 | 4 | |
| 19 | 2022 | 3 | |
| 20 | 2017 | 2 |
About Liling Wan
Liling Wan is a scholar working on Molecular Biology, Pathology and Forensic Medicine, Oncology, Cancer Research and Organic Chemistry, having authored 20 papers that have together received 1.7k indexed citations. Recurring topics across this work include Peptidase Inhibition and Analysis (8 papers), Cancer Mechanisms and Therapy (7 papers), Protein Degradation and Inhibitors (5 papers), Genomics and Chromatin Dynamics (4 papers), Histone Deacetylase Inhibitors Research (3 papers), RNA modifications and cancer (3 papers), RNA Research and Splicing (3 papers) and Ubiquitin and proteasome pathways (2 papers). The work is most often cited by research in Cancer Research (295 citations), Oncology (498 citations), Pathology and Forensic Medicine (266 citations), Molecular Biology (1.0k citations) and Geriatrics and Gerontology (32 citations). Liling Wan has collaborated with scholars based in United States, China and Hong Kong. Frequent co-authors include Yibin Kang, Klaus Pantel, Haitao Li, C. David Allis, Xiaobing Shi, Hong Wen, Yuanyuan Li, Tatyana Panchenko, Zhanyun Tang and Dan Zhao. Their work appears in journals such as Nature Communications, Cancer Research, Molecular Cell, Nature Chemical Biology and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.